Food and Drug Administration Center for Drug Evaluation and Research (CDER) Antiviral Drugs Advisory Committee May 19, 2005

First Page		Document Content
Date: 2005-05-25 15:51:21 Protease inhibitors Medicinal chemistry Pyridines Food and Drug Administration United States Department of Health and Human Services Tipranavir Boehringer Ingelheim Pharmaceutical drug Center for Drug Evaluation and Research Pharmacology Pharmaceutical sciences Clinical research		Food and Drug Administration Center for Drug Evaluation and Research (CDER) Antiviral Drugs Advisory Committee May 19, 2005 Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 29,50 KB Share Document on Facebook

	Notice : information de l’utilisateur Aptivus 250 mg capsules molles tipranavir Veuillez lire attentivement cette notice avant de prendre ce médicament car elle contient des informations importantes pour vous. Gardez DocID: 1lrxO - View Document
	Bijsluiter: informatie voor de gebruiker Aptivus 250 mg zachte capsules tipranavir Lees goed de hele bijsluiter voordat u dit geneesmiddel gaat innemen want er staat belangrijke informatie in voor u. Bewaar deze bijsluit DocID: 1kvu8 - View Document
	APTIVUS Soft Capsules Tipranavir Consumer Medicine Information (CMI) What is in this leaflet This leaflet answers some common DocID: 1gAFE - View Document
	PDF Document DocID: RNxu - View Document
	AIDS InfoNet www.aidsinfonet.org Fact Sheet Number 443 SAQUINAVIR (Invirase) DocID: RFm3 - View Document